EGFR and non-small cell lung carcinoma: Health economics studies on first-line TKIs for advanced NSCLC treatment found that the incremental cost per quality-adjusted life-year gained (ICER) by TKI was high (USD100,000–150,000 per QALY) in patients with low prevalence of EGFR mutation (9.5%-15%) [9, 10].